BCL2 and diffuse large B-cell lymphoma: Here, we used a collection of well-established Bcl-2-dependent DLBCL cell lines to assess the cell-death properties of two selective Bcl-2 inhibitors that target different domains of Bcl-2, namely ABT-199 (venetoclax), which targets the hydrophobic cleft of Bcl-2 and disrupts Bcl-2/Bim interactions [11], and BIRD-2, which targets the N-terminal BH4 domain of Bcl-2 and disrupts IP3R/Bcl-2 interactions [21].